Running Interference: RNAi with Silence Therapeutics' Craig Tooman
Business Of Biotech
00:00
How Do You Manage Your Organizational Structure?
As we advance in the and those those phases get larger and more expensive, we grow. And there's no question about that. We're in this phase now that as we see real excitement in the clinical outcomes, we need to actually grow into that. So that is that phase it we're in that needs to be resourced. Other companies are approaching us with a lot of interest in this field right now. You have hanso, you've probably seen that hansoa deal in china. We've got malancrot, and w got astrozenica.
Transcript
Play full episode
